Nidlegy was found to be well-tolerated and 149 out of the anticipated 214 patients have been safely treated. Data Safety Monitoring Board recommends to continue the study as planned.

(i) Study shows Philogen's proprietary immunocytokines are effective treatment for brain tumors.
(ii) Early promising findings from Philogen's Phase I/II study investigating the safety and efficacy of L19TNF monotherapy in patients with glioblastoma.
(iii) Philogen's proprietary cancer treatment found to be safe and well-tolerated.

Powerful Cell Guidance Systems' technology is being applied to the treatment of a disease that causes chronic pain for millions of people.

Golimumab is currently offered in the SmartJect® auto injector and UltraSafe® pre-filled syringes. SmartJect® and monthly dosing distinguish golimumab from other anti-TNFs and provide patient friendly administration of the product.